ENLV Enlivex Therapeutics

Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition

Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
EN
01/10/2020

Underlying

ENLVEnlivex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Enlivex Therapeutics

 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoart...

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology Ness-Ziona, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a poster at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology, taking place June 11-14, 2025, in Barcelona, Spain. The Company’s presentation will feature data from the ongoing clinical study evaluating Allocetr...

June 10, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.67
TBI TRUEBLUE INC.
SEDG SolarEdge Techn... ... (+24)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

TBI TRUEBLUE INC.
SEDG SOLAREDGE TECHNOLOGIES INC.
PSIX POWER SOLUTIONS INTERNATIONAL INC.
ENLV ENLIVEX THERAPEUTICS
OLLI OLLIE'S BARGAIN OUTLET HOLDINGS INC
FRPT FRESHPET INC
GSHD GOOSEHEAD INSURANCE
JAN JANONE INC
CURI CURIOSITYSTREAM INC (A)
PTLO PORTILLOS INC
ACHR ARCHER AVIATION INC
HTZ HERTZ GLOBAL HLDGS INC
QBTS D-WAVE QUANTUM INC.
WEST WESTROCK COFFEE COMPANY LLC
PDYN PALLADYNE AI CORP
VIK VIKING HOLDINGS LTD
LB LANDBRIDGE COMPANY LLC
CDTX CIDARA THERAPEUTICS INC.
LGCY LEGACY EDUCATION INC.
AEVA AEVA TECHNOLOGIES INC.
ALMU AELUMA INC
JNVR JANOVER INC
ACOG ALPHA COGNITION INC
PCT PROVIDENT CAP TR II SKIS 8.75%29
05/21/25 May 21, 2025 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Enlivex Selected to Present at Israeli BioMed 2025 Conference Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company has been selected to present at the upcoming Israeli BioMed 2025 Conference, taking place May 21–23, 2025 in Tel Aviv, Israel. The Company’s presentation is titled “Enlivex—Harnessing the Natural Healing...

May 20, 2025 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthrit...

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress Presentations to underscore AllocetraTM’s novel mechanism targeting immune imbalance in joint disease Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2025 World Congress on Osteoarthritis, taking place April 24-27, 2025, in Incheon (Seoul), Sou...

April 23, 2025 1 EN
 PRESS RELEASE
Free
ENLV Enlivex Therape...

Enlivex Announces Completion of Enrollment In The Phase II stage Of I...

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis. Overall, 133 patients were rando...

April 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch